Dr Reddy’s semaglutide supply delay knocks shares 6% in 2026

What Dr Reddy’s disclosed on July 9

Dr Reddy’s Laboratories said on Thursday, July 9, 2026, that it is delaying commercial supplies of semaglutide after identifying a quality-related issue linked to the active pharmaceutical ingredient (API) used in the drug. The company said certain batches were found to be out of specification.

In its communication, Dr Reddy’s said it is investigating the root cause and taking corrective measures to ensure product quality. The company also said the issue has no impact on patient safety. It added that there is no impact on the product’s existing global regulatory filings.

The company did not specify how long the supply delay would last and did not provide further details on the batches involved.

What “out of specification” means in this context

Dr Reddy’s used the term “out of specification” to describe the affected semaglutide batches. That phrasing typically indicates a batch has not met one or more predefined quality parameters, and it often triggers internal investigations and containment actions.

Here, the company explicitly linked the problem to the API used in the product. It said it is investigating the root cause and implementing measures to ensure product quality, indicating the issue is being handled within the company’s quality systems.

At the same time, Dr Reddy’s emphasised two points for stakeholders: there is no impact on patient safety, and there is no impact on existing global regulatory filings. Those statements suggest the company sees the matter as a quality non-conformance requiring resolution before supply, rather than a safety event.

Immediate market reaction: stock drops around 6%

The disclosure weighed on the stock in Thursday’s session. Dr Reddy’s Laboratories fell 6.29% to Rs 1,263.90 after the company said commercial supplies of certain batches of its semaglutide product will be delayed following the API-related quality issue.

Another reported intraday print showed the share price down about 6% to Rs 1,261.20 on the BSE. The move reflected investor sensitivity to execution risks in complex injectable launches, especially for high-demand metabolic therapies.

The company’s statement did not quantify the commercial impact of the delay, and it did not provide a revised supply timeline. With limited detail available, the market reaction largely tracked the uncertainty around how quickly the quality issue can be closed.

Company position on safety and regulatory filings

Dr Reddy’s said there is no impact on patient safety. It also stated that the matter does not affect the product’s existing global regulatory filings.

Those assurances are central because semaglutide is a regulated therapy and because filings and compliance status can influence both near-term supplies and longer-term market access. Dr Reddy’s framed the situation as a quality matter under investigation, rather than a change in the product’s regulatory standing.

The company also reiterated that it remains committed to ensuring reliable global supplies of the metabolic therapy.

What is known about the supply disruption

The company said “commercial supplies” will be delayed “for a certain period of time” until the issue is resolved. It did not specify whether the delay affects a particular market, customer set, or packaging configuration.

It also did not disclose the scale of the affected batches, when the quality deviation was detected, or whether alternative API sources or additional batches are available. The only explicit operational detail provided was that the issue is associated with the API used in the product.

Conference call scheduled to address questions

Dr Reddy’s management scheduled a conference call on July 9, 2026, to discuss the development and answer questions from participants. The stated timing was 4:30 p.m. IST.

The company also shared the call window as 16:30 to 17:00 Indian Standard Time (IST) and 07:00 to 07:30 Eastern Time (ET). Such calls typically help clarify scope, timelines, and mitigation plans, but any additional specifics would depend on what management discloses.

Background: why semaglutide matters to Dr Reddy’s

Semaglutide is a glucagon-like peptide-1 (GLP-1) therapy used in metabolic conditions and is central to a fast-growing treatment category globally. Dr Reddy’s has been positioning itself in this space through generic semaglutide efforts.

In its FY2025-26 annual report, Dr Reddy’s said it is the first company to secure market authorization for generic semaglutide in India and Canada. Separately, the company has indicated plans to sell 12 million injectable semaglutide pens in the first year of launch, according to earlier regulatory filings cited in the provided material.

Reuters also reported earlier that Dr Reddy’s Managing Director G.V. Prasad said the company planned competitive pricing that could be up to 60% lower than the branded counterpart.

Market impact: execution risk becomes the focus

Thursday’s decline highlights how quickly sentiment can shift when a launch or supply plan hits a quality hurdle, even when the company says there is no patient safety impact. For investors, the immediate question is duration: Dr Reddy’s did not state when commercial supplies would normalise.

For the broader Indian pharma sector, the episode underlines the importance of API consistency and quality controls, particularly for complex peptides and injectables. Even small deviations can delay release, affect supply schedules, and increase scrutiny from buyers and partners.

Why the development matters

Semaglutide sits at the intersection of strong demand, intense competition, and high manufacturing complexity. Dr Reddy’s statement points to an API-related issue, and in regulated markets that typically requires evidence-backed closure of root cause and corrective actions before normal shipments resume.

The company’s emphasis on “no impact” to patient safety and existing regulatory filings helps narrow the issue to batch quality and supply timing rather than a broader compliance event. Still, the absence of a defined timeline leaves uncertainty, which the market priced in immediately.

Conclusion

Dr Reddy’s has delayed commercial supplies of semaglutide after some batches were found out of specification due to an API-related issue. The stock fell about 6% as the company began a root-cause investigation and corrective measures, while stating patient safety and existing global regulatory filings remain unaffected.

The next near-term milestone is the company’s management conference call scheduled for July 9, 2026, where investors will look for clarity on the scope of affected batches and the expected duration of the supply delay.